MaxCyte Inc. (NASDAQ:MXCT) saw an upside of 1.92% to close Friday at $3.72 after adding $0.07 on the day. The 5-day average trading volume is 370,560 shares of the company’s common stock. It has gained $3.89 in the past week and touched a new high 2 times within the past 5 days. An average of 344,965 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 372,722.
MXCT’s 1-month performance is -23.61% or -$1.17 on its low of $3.60 reached on 08/18/23. The company’s shares have touched a 52-week low of $3.57 and high of $7.50, with the stock’s rally to the 52-week high happening on 01/31/23. YTD, MXCT has lost -31.87% or -$1.74 and has reached a new high 6 times. However, the current price is down -50.40% from the 52-week high price.
Insider Transactions
MXCT stock investors last saw insider trading activity on Jul 26.Johnston John Joseph (Director) most recently sold 5,000 shares at $4.75 per share on Jul 26. This transaction cost the insider $23,750. President and CEO, Doerfler Douglas, sold 16,757 shares at a price of $5.02 on Jul 12. Then, on Jul 11, President and CEO Doerfler Douglas sold 12,798 shares at a price of $5.04 per share. This transaction amounted to $64,502.
Valuation Metrics
Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.28 while the price-to-book (PB) in the most recent quarter is 1.59.
MaxCyte Inc.’s quick ratio for the period ended June 29 was 17.10, with the current ratio over the same period at 17.90. In terms of profitability, the gross margin trailing 12 months is 87.00%. The trailing 12-month EBITDA margin is -55.54%. The firm’s gross profit as reported stood at $39.16 million against revenue of $44.26 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 21.41% to -$10.51 million, while revenue of -$10.88 million was -3.52% off the previous quarter. Analysts expected MXCT to announce -$0.1 per share in earnings in its latest quarter, but it posted -$0.1, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$13.96 million. MXCT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 30.22 million, with total debt at $16.21 million. Shareholders hold equity totaling $103.5 million.
Let’s look briefly at MaxCyte Inc. (MXCT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 24.71% to suggest the stock is trending oversold, with historical volatility in this time period at 65.63%.
The stock’s 5-day moving average is $3.73, reflecting a -3.12% or -$0.12 change from its current price. MXCT is currently trading -24.70% above its 20-day SMA, -9.49% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -16.78% and SMA200 by-46.24%.
Stochastic %K and %D was 5.74% and 5.26% and the average true range (ATR) pointed at 0.19. The RSI (14) points at 28.48%, while the 14-day stochastic is at 12.57% with the period’s ATR at 0.20. The stock’s 9-day MACD Oscillator is pointing at -0.24 and -0.41 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for MXCT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate MXCT as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is MXCT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $12.00, with their median price target at $10.02. Looking at these predictions, the average price target given by analysts is for MaxCyte Inc. (MXCT) stock is $9.96.
